Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

CULLINAN ONCOLOGY, INC.

(CGEM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Business Summary
Cullinan Oncology, Inc., formerly Cullinan Management, Inc. is a biopharmaceutical company. The Company is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. The Company’s lead candidate, CLN-081 in a Phase I/IIa, is an orally available small molecule designed as an irreversible epidermal growth factor receptor (EGFR), inhibitor that is designed to selectively target cells expressing mutant EGFR variants, including EGFR exon 20 insertion (EGFRex20ins), mutations, with relative sparing of cells expressing wild type EGFR. The Company’s evaluating CLN-081 as a treatment for non-small cell lung cancer (NSCLC), in adult patients with EGFRex20ins mutations in a Phase I/IIa trial. The Company’s other product candidates include CLN-049, CLN-619, CLN-617, CLN-978, Opal and Jade.

Number of employees : 31 people.
Sales per Business
20202021Delta
Cancer Therapeutics--18.94100%-
USD in Million
Sales per region
20202021Delta
United States--18.94100%-
USD in Million
Managers
Name Title Age Since
Nadim Ahmed President, Chief Executive Officer & Director 54 2021
Jeffrey Trigilio Chief Financial Officer 38 2020
Patrick A. Baeuerle, Dr. Chief Scientific Officer 64 2022
Jeffrey Jones, Dr. Chief Medical Officer 51 2022
Kevin Johnston Chief Technical Operations Officer - 2022
Jacquelyn Sumer Secretary, Chief Legal & Compliance Officer - 2022
Chad Messer, Dr. Vice President-Investor Relations - 2022
Jennifer Michaelson, Dr. Chief Development Officer-Biologics 55 2018
Corinne Savill, Dr. Chief Business Officer 62 2017
Stephen Andre Chief Human Resources Officer 60 2022
Members of the board
Name Title Age Since
Anthony Adam Rosenberg Independent Director 69 2017
Thomas Ebeling Independent Director 63 2017
Stephen W. Webster Independent Director 61 2020
Nadim Ahmed President, Chief Executive Officer & Director 54 2021
Anne-Marie Martin, Dr. Director 50 2022
David P. Ryan, Dr. Director 56 2022
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 39,324,370 37,684,272 95.8% 0 0.0% 95.8%
Shareholders
NameEquities%
MPM Oncology Impact Management LP 7,913,887 17.3%
Bioimpact Capital LLC 7,648,268 16.7%
BVF Partners LP 7,509,059 16.4%
CHI Advisors LLC 3,243,185 7.09%
F2 Capital Ventures LLP 3,132,022 6.84%
The Vanguard Group, Inc. 2,732,547 5.97%
Eventide Asset Management LLC 1,440,145 3.15%
Morana Jovan-Embiricos 1,344,328 2.94%
AIG Asset Management (U.S.) LLC 1,223,712 2.67%
Nextech Invest AG 1,221,145 2.67%
Brand Portfolio
In partnership withAllbrands.markets
More brands of Cullinan Oncology, Inc.